Latest news

1 year 11 months ago
The National Institute for Clinical Excellence (NICE) has today issued appraisal consultation documents for three new hepatitis C therapies; ledipasvir-sofosbuvir (Harvoni), daclatasvir (Daklinza, and ombitasvir/paritaprevir/ritonavir (with or without dasabuvir). A summary of the recommendations, which at this stage are preliminary, are below: Ledipasvir-sofosbuvir Genotype 1
1 year 11 months ago
Today, World Hepatitis Day 28th July 2015, offers an important opportunity to look at the progress that has been made in addressing hepatitis C in the UK and across the world to date, and to reflect on the opportunities that now exist to tackle it.
1 year 11 months ago
Nicola Sturgeon MSP, the First Minister of Scotland, today joined with opposition leaders to pledge her support for World Hepatitis Day, and re-iterated the Scottish Government’s commitment to tackling viral hepatitis.
1 year 11 months ago
The Hepatitis C Trust is joining forces with Manchester Public Health to promote hepatitis C awareness and testing ahead of World Hepatitis Day (28th July).  It is estimated that over 5,000 people in Manchester are living with hepatitis C, although half of these people are undiagnosed. To raise awareness of the ‘silent killer’, the charity will be offering free on-the-spot hepatitis C tests at the following times and locations:
1 year 11 months ago
Addaction is embracing World Hepatitis Day in a big way this year. Packs with promotional materials and information are being sent out to all participating services this week.
1 year 12 months ago
The Hepatitis C Trust has won a Communique Award for Excellence in Media Relations for its work with Paradigm Communications, in launching the report from the All-Party Parliamentary Hepatology Group's expert Inquiry into the burden of liver disease.
1 year 12 months ago
All participants in the TURQUOISE-III trial, which enrolled HCV genotype 1b patients with compensated liver cirrhosis, achieved sustained virological response using AbbVie's Viekira Pak or "3D" regimen without ribavirin, according to a company announcement this week. The advent of interferon-free direct-acting antiviral therapy has revolutionized hepatitis C treatment. But challenges remain for the most difficult-to-treat patients, including those with advanced liver disease.
2 years 1 week ago
Health Secretary Jeremy Hunt must intervene to overturn attempts by NHS England to severely limit the number of people with hepatitis C receiving life-saving treatments, 14 charities and top liver doctors have written to him to say.
2 years 2 weeks ago
Today NHS England published a commissioning policy that will allow people with hepatitis C-related cirrhosis access to new treatments. NHS England has announced (10 June 2015) that it will be investing an estimated further £190 million in new cures for hepatitis C, on top of the approximately £40 million which began last year as part if its early access scheme to treat people with decompensated cirrhosis.
2 years 2 weeks ago
The estimated 37,000 people in Scotland with hepatitis C received the good news yesterday that the Scottish Medicines Consortium (SMC) has now approved Viekirax (ombitasvir/paritaprevir/ritonavir) and Exviera (dasabuvir) for use within NHS Scotland.  Viekirax has been approved for use in combination with Exviera, with or without ribavirin, for the treatment of genotype 1 chronic hepatitis C in adults, while Viekirax has been approved for use in combination with ribavirin for the treatment of genotype 4 patients.

Pages